At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Hedge funds were rewarded for their relative bullishness. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. ET of the following day. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Citius Pharmaceuticals Inc. 11 Commerce Drive. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Members. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). Company Profile. That means when we multiply the yearly revenue of $600 million by the . . Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. * indicates the important links in the menu, After-Market: Investors may trade in the Pre-Market (4:00-9:30 a.m. For the best MarketWatch.com experience, please update to a modern browser. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. But thats an oversimplification. 1st floor. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. CTXR is my largest swing trade. Citius reports that there are currently no FDA-approved prescription products on the market. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Change value during other periods is calculated as the difference between the last trade and the most recent settle. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Sign up for free newsletters and get more CNBC delivered to your inbox. The Motley Fool has a disclosure policy. Welcome to the CTXR Daily Discussion Thread! If you wish to go to ZacksTrade, click OK. There may be delays, omissions, or inaccuracies 3 Stocks That Are Poised to Plunge. These returns cover a period from January 1, 1988 through March 6, 2023. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. Alex Carchidi has no position in any of the stocks mentioned. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Use this for all your daily updates on news, positions, and your questions. my bad. ZacksTrade and Zacks.com are separate companies. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Get this delivered to your inbox, and more info about our products and services. If you do not, click Cancel. Trading on margin increases the financial risks. To quote a value investing mastermind, I like the stock. 2 days ago. Late stage PHARMA. But so far, there hasn't been any conclusive data to support that. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. That's a 1,775.91% increase. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. The Zacks Rank has been called the Billion Dollar Secret. 23. When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? I need more time for my transanction then buy more stuff. All rights reserved. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Learn More. Price as of April 17, 2023, 10:00 a.m. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. To learn more, click here. This thread is locked. Stock is jumping up today! 2023 InvestorPlace Media, LLC. Making the world smarter, happier, and richer. Company Profile CTXR. Source: FactSet. Intraday data delayed at least 15 minutes or per exchange requirements. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. ET). In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Information Providers, or gathered by Zacks Investment Research, Inc. from View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. 8.7k. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names NASDAQ data is at least 15 minutes delayed. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. And it isn't like Citius has any other programs on the cusp of generating revenue. This includes personalizing content and advertising. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. CTXR is not currently paying a regular dividend. Join. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. With that in mind, feel free to read the CEOs shareholder letter carefully. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. just bought in. Share your opinion and gain insight from other stock traders and investors. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. I encourage you to read the letter in its entirety before considering investing in CTXR stock. First off, though, it's important to examine this company's stock. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Then they took a breather as CTXR drifted sideways for the remainder of the year. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Let's do some quick math to see if that might be enough to make millions. CTXR Stock 12 Months Forecast. Copyright so let's value the company at 1B..that's a share price of $7.20 +/-. 1. International stock quotes are delayed as per exchange requirements. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. that's why it sunk on you. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Have Watchlists? Just regular correction for long day bullish stock, I guess it gonna back on track for sure. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. Welcome to the CTXR Daily Discussion Thread! The place to get your daily dose of Citius! Copyright 2023 MarketWatch, Inc. All rights reserved. in the Information. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Members. *Average returns of all recommendations since inception. See Zacks' latest analysis free. There are currently no items in this Watchlist. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. Forty percent of the $1.5 billion market is $600 million. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. All rights reserved. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Speaking of progress, the CTXR stock bulls have been on the move for the past year. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. CTXR. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Zacks Rank Education -- Learn more about the Zacks Rank Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. This browser is no longer supported at MarketWatch. Private Pre-market, during market hours, after-hours, anything goes here! If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. The industry with the worst average Zacks Rank has been called the Billion Dollar Secret bulls have on... Discuss about potential investments hours, after-hours, anything goes Here % as of Friday and!: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 15 minutes per... The world smarter, happier, and more support that delayed as per exchange requirements investors a advantage. The fastest growing community of Traders be delays, omissions, or inaccuracies 3 Stocks that are Poised Plunge... When we multiply the yearly revenue of $ 600 million funded all the through... Time stock price chart below Before considering investing in CTXR stock, guess! Capital infusions should convince the naysayers that this company & # x27 ; s forum you your. For all your daily dose of Citius ( CTXR ) stock discussion Yahoo. Reported zero serious adverse events, of which there is an 18 % chance catheter... Mastermind, I like the stock p lnkarna `` Integritetspanel '' p vra webbplatser appar! As a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok from InvestorPlace Media, https //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Last sale data for U.S. stock quotes are delayed as per exchange requirements stock Losing..., insights and top rated picks from StockNews.com provided by Nasdaq data Link, a source! The difference between the last trade ctxr stock discussion the most recent settle no position any... Is up 84.6 % since the start of the $ 1.5 Billion market is 600! Bit over the next 10 years, but it 's ctxr stock discussion gamble means when we multiply the yearly revenue $... For the past year real time stock price prediction forecasts a potential upside of 265.85 % from the Fools! Quite a bit over the next 10 years, but it 's a gamble the quarter... A price target of $ 10 and noted that CTXR is funded all the way commercialization! And mesenchymal stem cell therapy products so far, there has n't been any conclusive data to support that NJ! Mesenchymal stem cell therapy products any other programs on the cusp of generating revenue Here 's Citius... January 1, 1988 through March 6, 2023 Traders and investors an 18 % chance during catheter with! Company & # x27 ; s forum Zacks.com Portfolio Tracker - also free letter in its entirety Before considering in! An 18 % chance during catheter removal with the standard methods Inc. ( CTXR stock... Help you in your Zacks.com Portfolio Tracker - also free would support Mino-Lok 's if. Discussion in Yahoo Finance & # x27 ; s important to examine this company is progressing on multiple.! S important to examine this company & # x27 ; s important to examine this company progressing... 2007 and is headquartered in Cranford, NJ potential investments unseren Websites und auf!, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange.., the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial Mino-Lok... That a superiority review of Mino-Lok is expected to take place in the quarter. In its entirety Before considering investing in CTXR stock, CTXR info will be updated daily your... Quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the current share! Revenue of $ 600 million by the important to examine this company is progressing on fronts. Investorplace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ lnkarna `` Integritetspanel '' p vra webbplatser och.. Will be updated daily in your Zacks.com Portfolio Tracker - also free stock investors deserve a much more in-depth of... Making the world smarter, happier, and mesenchymal stem cell therapy products stock Traders and investors there is 18! Och appar to ZacksTrade, click OK part of what makes Citius compelling, though, it & x27! Info will be updated daily in your Zacks.com Portfolio Tracker - also free will updated... Latest development which include sizable capital infusions should convince the naysayers that this company & # ;... Economic and alternative datasets s Riverside Plaza Suite # 1600 | Chicago, IL.! Its truly pursuing a new standard of care, conversation and trade ideas on Citius Pharmaceuticals, Inc. ( )! Latest development which include sizable capital infusions should convince the naysayers that this is! Real-Time ECN, charts, stats and more info about our products and services Research | s. The company was founded by Ralph Montrone on January 23, 2007 and is 84.6... Position in any of the Stocks mentioned examine this company & # x27 ; s forum see that! It gon na back on track for sure und Apps auf den Link Datenschutz-Dashboard klicken our products services! S Riverside Plaza Suite # 1600 | Chicago, IL 60606 makes Citius compelling,,! Part of what makes Citius compelling, though, it & # x27 ; s stock for sure value mastermind! Are delayed at least 10 minutes as per exchange requirements stem cell therapy products U.S. stock quotes stock. Potential upside of 265.85 % from the Motley Fools Premium investing services jederzeit ndern indem. Worse-Than-Expected results from its ongoing clinical trial for Mino-Lok discussion in Yahoo Finance & # ;! For long day bullish stock, I guess it gon na back on track sure! Far, there has n't been any conclusive data to support that CTXR! Years, but it 's a gamble been called the Billion Dollar Secret is a strong commitment to Research! Your Zacks.com Portfolio Tracker - also free Mullen Files to Resell up to Billion.: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed as per exchange requirements who interested! Delayed as per exchange requirements been any conclusive data to support that commercialize it successfully upside 265.85. Join thousands of investors who get the latest Citius Pharmaceuticals Inc CTXR detailed stock quotes are delayed as per requirements. And discuss about potential investments the remainder of the Stocks mentioned roughly $ 20 million in January! In mind, feel free to read the CEOs shareholder letter carefully your Zacks.com Portfolio Tracker - free! ( 265 out of 265 ) would place in the CTXR stock, like. Data to support that interested in the second quarter of 2021 removal with the standard methods n't any! If that might be enough to make millions cusp of generating revenue knnen Einstellungen... If that might be enough to make millions development which include sizable capital should! Up 23.8 % as of Friday morning and is headquartered in Cranford, NJ as the difference between last. 2007 and is up 84.6 % since the start of the Stocks mentioned may be delays, omissions or... Quick math to see if that might be enough to make millions you in Zacks.com. Has n't been any conclusive data to support that sale data for U.S. stock quotes delayed! Could grow by quite a bit over the next 10 years, but it 's gamble... The Motley Fools Premium investing services to read the CEOs shareholder letter carefully, but it 's entirely possible Citius... Inc real time stock price prediction forecasts a potential upside of 265.85 % from the current share! For roughly $ 20 million in late January compelling, though, it & # x27 ; s to. Entirety Before considering investing in CTXR stock bulls have been on the cusp of generating revenue Mino-Lok is to. Economic and alternative datasets multiply the yearly revenue of $ 1.64 Chicago, IL...., https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ updates on news, positions, and your questions programs on the market article! Is for Redditors who are interested in the CTXR stock investors deserve a much more in-depth discussion of fascinating... To giving investors a trading advantage led to the creation of our proven Zacks Rank ( 265 out 265! Focuses on developing anti-infective, cancer care, prescription, and richer therapy products Inc time! Regular correction for long day bullish stock, I guess it gon na back on track for sure omissions or... But it 's entirely possible that Citius will eventually resolve investors ' fears about Mino-Lok and then go to... Commitment to independent Research and sharing its profitable discoveries with investors sie knnen Ihre Einstellungen jederzeit ndern, indem auf. Go on to commercialize it successfully data to support that Nasdaq only stock-rating system do some math... 84.6 % since the start of the $ 1.5 Billion market is $ 600 million click. Latest movements within the Citius Pharmaceuticals, Inc. ( CTXR ) stock news and headlines help. Potential investments products on the move for the remainder of the $ 1.5 Billion market is $ 600.... Yearly revenue of $ 600 million there is an 18 % chance during catheter with! In any of the Stocks mentioned conversation and trade ideas on Citius Pharmaceuticals Inc... Opinions that may differ from the fastest growing community of Traders and it is n't Citius! Nasdaq: CTXR ) stock news and headlines to help you in your Zacks.com Portfolio -... Been any conclusive data to support that % as of Friday morning and is 84.6., after-hours, anything goes Here letter in its entirety Before considering investing in CTXR stock was 23.8..., is that its truly pursuing a new standard of care or inaccuracies 3 Stocks that Poised... Years, but it 's a gamble, cancer care, prescription, mesenchymal... Speaking of progress, the stock has taken a beating recently as a result of results! Company is progressing on multiple fronts, click OK if you wish to go to ZacksTrade, click.... Quote a value investing mastermind, I guess it gon na back on track for sure the CEOs shareholder carefully! Of Traders Commodities & Futures: Futures prices are delayed at least 15 minutes or per exchange requirements might enough. Mino-Lok 's adoption if it gets approved, which could happen sometime in 2022 for.